-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 EqpRRqIpA7TD7bfZrKLOQG6mbKCC23SC03JknQ/oAfmAIc0swebENMw2irbxspQn
 bFXQLX0GKkLjHM45ri9xVQ==

<SEC-DOCUMENT>0001317757-10-000004.txt : 20100225
<SEC-HEADER>0001317757-10-000004.hdr.sgml : 20100225
<ACCEPTANCE-DATETIME>20100225162410
ACCESSION NUMBER:		0001317757-10-000004
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20100224
FILED AS OF DATE:		20100225
DATE AS OF CHANGE:		20100225

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			ALLEN LEE F MD PhD
		CENTRAL INDEX KEY:			0001408474

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-10865
		FILM NUMBER:		10633887

	MAIL ADDRESS:	
		STREET 1:		C/O AMAG PHARMACEUTICALS, INC.
		STREET 2:		125 CAMBRIDGEPARK DRIVE, 6TH FLOOR
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02140

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMAG PHARMACEUTICALS INC.
		CENTRAL INDEX KEY:			0000792977
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				042742593
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		100 HAYDEN AVENUE
		CITY:			LEXINGTON
		STATE:			MA
		ZIP:			02140
		BUSINESS PHONE:		6174972070

	MAIL ADDRESS:	
		STREET 1:		100 HAYDEN AVENUE
		CITY:			LEXINGTON
		STATE:			MA
		ZIP:			02140

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADVANCED MAGNETICS INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>primary_doc.xml
<DESCRIPTION>PRIMARY DOCUMENT
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0303</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2010-02-24</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0000792977</issuerCik>
        <issuerName>AMAG PHARMACEUTICALS INC.</issuerName>
        <issuerTradingSymbol>AMAG</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001408474</rptOwnerCik>
            <rptOwnerName>ALLEN LEE F MD PhD</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O AMAG PHARMACEUTICALS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>100 HAYDEN AVENUE</rptOwnerStreet2>
            <rptOwnerCity>LEXINGTON</rptOwnerCity>
            <rptOwnerState>MA</rptOwnerState>
            <rptOwnerZipCode>02421</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>Chief Medical Officer, Exec VP</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Stock Options</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>38.29</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2010-02-24</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness>
                <value></value>
            </transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>16250</value>
                </transactionShares>
                <transactionPricePerShare>
                    <footnoteId id="F2"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <value>2020-02-24</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>16250</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>16250</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
        <derivativeTransaction>
            <securityTitle>
                <value>Restricted Stock Unit</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <footnoteId id="F3"/>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2010-02-24</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness>
                <value></value>
            </transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>5417</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F4"/>
            </exerciseDate>
            <expirationDate>
                <footnoteId id="F5"/>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>5417</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>5417</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">Grant of stock option pursuant to the AMAG Pharmaceuticals, Inc. Amended and Restated 2007 Equity Incentive Plan.  This option is exercisable in four equal installments.  The first installment will vest on February 24, 2011, the first anniversary of the grant, and the next three installments will vest on February 24, 2012, February 24, 2013 and February 24, 2014.</footnote>
        <footnote id="F2">Price is not applicable.</footnote>
        <footnote id="F3">Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.</footnote>
        <footnote id="F4">Grant of restricted stock unit pursuant to the AMAG Pharmaceuticals, Inc. Amended and Restated 2007 Equity Incentive Plan.  This grant is exercisable in four equal installments.  The first installment will vest on February 24, 2011, the first anniversary of the grant, and the next three installments will vest on February 24, 2012, February 24, 2013 and February 24, 2014.</footnote>
        <footnote id="F5">Not applicable.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>Joseph L. Farmer, attorney-in-fact</signatureName>
        <signatureDate>2010-02-25</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----